Table 2 Baseline table of vision loss
From: Vision loss in patients with giant cell arteritis treated with tocilizumab
All | Normal vision at baseline | Vision loss before baseline | p value | |
|---|---|---|---|---|
n (%) or median (IQ range) | n (%) or median (IQ range) | n (%) or median (IQ range) | ||
Total N | N = 186 | N = 165 | N = 21 | |
Female | 116 (62%) | 101 (61%) | 15 (71%) | 0.475 |
Age at diagnosis | 71.0 (63.0; 77.0) | 70.0 (63.0; 76.0) | 74.0 (69.5; 82.0) | 0.032 |
Weight [kg] | 70.0 (59.0; 83.4) | 71.9 (59.1; 83.3) | 61.6 (54.1; 85.5) | 0.178 |
BMI [kg/m2] | 24.9 (22.0; 28.4) | 25.2 (22.0; 28.4) | 23.7 (21.3; 27.7) | 0.237 |
First CRP (mg/L) | 50.0 (20.0; 99.0) | 54.5 (21.0; 101.3) | 20.0 (3.5; 47.5) | 0.002 |
First ESR (mm/h) | 70.0 (40.0; 86.3) | 70.0 (40.0; 87.5) | 50.0 (34.0; 78.0) | 0.197 |
ACR Criteria 1990 | 109 (59%) | 94 (57%) | 15 (71%) | 0.245 |
Cranial symptoms (incl. Visual sympt.) | 124 (67%) | 103 (62%) | 21 (100%) | < 0.001 |
Visual symptoms | 70 (38%) | 49 (30%) | 21 (100%) | < 0.001 |
Permanent vision loss | 21 (11%) | 0 (0%) | 21 (100%) | < 0.001 |
Headache | 93 (50%) | 83 (50%) | 10 (48%) | 1.000 |
Jaw claudication | 48 (26%) | 38 (23%) | 10 (48%) | 0.031 |
Scalp tenderness | 42 (23%) | 36 (22%) | 6 (29%) | 0.579 |
Claudication of tongue | 2 (1%) | 1 (1%) | 1 (5%) | 0.214 |
Fever ≥ 38 °C | 35 (19%) | 35 (21%) | 0 (0%) | 0.015 |
Weight loss > 2 kg within 4 weeks | 50 (27%) | 42 (25%) | 8 (38%) | 0.295 |
Night sweat | 33 (18%) | 29 (18%) | 4 (19%) | 1.000 |
Polymyalgia rheumatica | 90 (48%) | 84 (51%) | 6 (29%) | 0.062 |